McKechnie Duncan 4

What Happened
McKechnie Duncan, EVP and Chief Commercial Officer of Vertex Pharmaceuticals (VRTX), sold 2,633 shares on 2026-03-11 at $498.42 per share, generating proceeds of approximately $1,312,340. The transaction is reported as a sale (S) and described as an open-market or private sale.

Key Details

• Transaction date & price: 2026-03-11 at $498.42 per share.
• Total proceeds: ~$1,312,340.
• Shares owned after transaction: not disclosed in the provided filing.
• Footnote: The sale was made pursuant to Mr. McKechnie’s company-approved Rule 10b5-1 trading plan entered 11/25/2025.
• Filing timeliness: Form 4 filed 2026-03-13 for a 2026-03-11 transaction — filed within the standard two business-day window, not late.

Context
Sales executed under a prearranged 10b5-1 plan are typically scheduled in advance and are generally viewed as routine liquidity events rather than direct signals of insider sentiment. This was a sale (not a purchase), so it does not indicate an additional personal buy-side conviction.